Choosing biological agents for the treatment of psoriatic arthritis
The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:148 |
|---|---|
| Enthalten in: |
Revista medica de Chile - 148(2020), 5 vom: 05. Mai, Seite 657-664 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto |
|---|
| Beteiligte Personen: |
Ibáñez, Sebastián [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.01.2021 Date Revised 28.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4067/S0034-98872020000500657 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319636410 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319636410 | ||
| 003 | DE-627 | ||
| 005 | 20231225171855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.4067/S0034-98872020000500657 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319636410 | ||
| 035 | |a (NLM)33399759 | ||
| 035 | |a (PII)S0034-98872020000500657 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Ibáñez, Sebastián |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Choosing biological agents for the treatment of psoriatic arthritis |
| 246 | 3 | 3 | |a Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2021 | ||
| 500 | |a Date Revised 28.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 700 | 1 | |a Valenzuela, Francisca |e verfasserin |4 aut | |
| 700 | 1 | |a Valenzuela, Omar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista medica de Chile |d 1945 |g 148(2020), 5 vom: 05. Mai, Seite 657-664 |w (DE-627)NLM00019624X |x 0717-6163 |7 nnns |
| 773 | 1 | 8 | |g volume:148 |g year:2020 |g number:5 |g day:05 |g month:05 |g pages:657-664 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4067/S0034-98872020000500657 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 148 |j 2020 |e 5 |b 05 |c 05 |h 657-664 | ||